Evaxion A/S (EVAX)
Nasdaq: EVAX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2020
Who runs Evaxion A/S
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Tayton-Martin Helen Katrina
Chief Executive Officer. First filing Mar 2026, latest Mar 31, 2026, 0 filings in all.
Officers reporting now
5
of 10 people with a filing in the last fifteen months
Directors reporting now
5
10 people on the record since 2026
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Mattsson Andreas Holm | CAIO Chief AI Officer | Apr 2026 | Apr 10, 2026 | none |
| Tayton-Martin Helen Katrina | Chief Executive Officer | Mar 2026 | Mar 31, 2026 | none |
| Schmidt Thomas Frederik | Chief Financial Officer | Mar 2026 | Mar 27, 2026 | none |
| Rono Birgitte | Chief Scientific Officer | Mar 2026 | Mar 27, 2026 | none |
| Evaxion A/s | Chief Financial Officer | Mar 2026 | Mar 18, 2026 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bitsch-Norhave Jens | director | Apr 2026 | Apr 24, 2026 | none |
| Soegaard Marianne | director | Apr 2026 | Apr 2, 2026 | none |
| Wegner Lars Aage Staal | director | Apr 2026 | Apr 1, 2026 | none |
| Prego Roberto | director | Mar 2026 | Mar 27, 2026 | none |
| Holtug Lars | director | Mar 2026 | Mar 18, 2026 | none |
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.